Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis

Stock Information for Kezar Life Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Kezar Life Sciences Inc.

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)
Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders
KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its Shareholders
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2025
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.